Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings

Abbott Laboratories (NYSE:ABT) is included among the 15 Best Consistent Dividend Stocks to Buy Right Now.

Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings

On April 6, Evercore ISI analyst Vijay Kumar lowered the firm’s price recommendation on Abbott Laboratories (NYSE:ABT) to $134 from $138. It maintained an Outperform rating on the shares. The update came as part of the firm’s Q1 preview for medical technology and life science tools.

On March 31, BTIG also lowered its price goal on Abbott to $131 from $140 and maintained a Buy rating. The firm said it is updating its model for Abbott Labs to include the Exact Sciences business, following the completion of that acquisition last week, the analyst noted in a research note. BTIG also pointed to new data from the Tri.Fr trial of Abbott’s TriClip, presented at the American College of Cardiology Scientific Session. The study did not allow patients in the control medical therapy arm to cross over to TriClip treatment. It showed a reduction in the TriClip group for a composite outcome that included first hospitalization for heart failure, tricuspid valve surgery, or cardiovascular death.

Abbott Laboratories (NYSE:ABT) operates as a global healthcare company. Its business focuses on the discovery, development, manufacture, and sale of a broad range of healthcare products. The company reports across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

While we acknowledge the risk and potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Cheapest Stocks with Highest Dividends and 14 Cheap DRIP Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.